In Silico Study and Validation of Natural Compounds Derived from Macleaya cordata as a Potent Inhibitor for BTK

Authors

  • Ayobami Fidelix Department of Neurosurgery, University of Texas, USA
  • Tomilola Akingbade Computer-Aided Therapeutic Discovery and Design Platform, Federal University of Technology, Nigeria
  • Jatin Jangra Department of Pharmaceutical Engineering and Technology, Indian Institute of Technology, India
  • Babatunde Olabuntu Department of Biochemistry, University of Ibadan, Nigeria
  • Olutola Adeyemo Department of Obstetrics and Gynecology, Federal Teaching Hospital, Nigeria
  • Juwon Akingbade Department of Computer Engineering, Federal University Oye Ekiti, Nigeria https://orcid.org/0009-0003-4347-4759

DOI:

https://doi.org/10.47852/bonviewMEDIN52024239

Keywords:

machine learning modeling, B-cell malignancies, Bocconarborine B, ibrutinib, molecular dynamic simulation

Abstract

Bruton's tyrosine kinase (BTK) is a kinase of the TEC family expressed in B cells and other hematopoietic cells, but it's not expressed in T cells. B-cell malignancies such as multiple myeloma and chronic lymphocytic leukemia have been shown to have a high expression of BTK, thereby displaying oncogenic activities in these diseases, triggering the discovery of BTK inhibitors. The study investigated computationally the phytochemical present in M cordata as novel BTK inhibitor with high efficacy in treating B-cell malignancies. Chelidimerine, Bocconarborine A, and Bocconarborine B show a high binding affinity of -13.7, -13.3, and -12.9, respectively. This study was validated using molecular dynamic stimulation to indicate the stability and interaction of the ligand with the targeted protein. Bocconarborine B has the best binding energy of -30.94kcal/mol compared to Ibrutinib, with a binding energy of -22.46kcal/mol. The identified hit compounds from this study were subjected to half maximum inhibitory concentration prediction (IC50) using machine learning modeling; the result shows that Bocconarborine B has the best IC50 of 48.98nM. This study is subject to validation via in vivo and in vitro studies.

 

Received: 3 September 2024 | Revised: 18 December 2024 | Accepted: 25 December 2024

 

Conflicts of Interest

The authors declare that they have no conflicts of interest to this work.

 

Data Availability Statement  

The data that support this work are available upon reasonable request to the corresponding author.

 

Author Contribution Statement

Ayobami Fidelix: Conceptualization, Methodology, Formal analysis, Resources, Writing - original draft, Writing - review & editing, Supervision. Tomilola Akingbade: Conceptualization, Methodology, Formal analysis, Resources, Writing - original draft, Writing - review & editing, Project administration. Jatin Jangra: Software, Validation, Resources. Babatunde Olabuntu: Software, Validation, Resources. Olutola Adeyemo: Writing - review & editing, Visualization. Juwon Akingbade: Investigation, Data curation, Writing - review & editing.


Downloads

Published

2025-01-08

Issue

Section

Research Articles

How to Cite

In Silico Study and Validation of Natural Compounds Derived from Macleaya cordata as a Potent Inhibitor for BTK. (2025). Medinformatics. https://doi.org/10.47852/bonviewMEDIN52024239